Patient-centric trials for therapeutic development in precision oncology von Biankin, Andrew V., Piantadosi, Steven, Hollingsworth, Simon J.

Volltext

Precision medicine in oncology drug development: a pharma perspective von Hollingsworth, Simon J.

Volltext

The National Lung MATRIX Trial: Cancer Research UK, in partnership with AstraZeneca and Pfizer von Hollingsworth, Simon J

Volltext

Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study von Yap, Timothy A, Krebs, Matthew G, Postel-Vinay, Sophie, El-Khouiery, Anthony, Soria, Jean-Charles, Lopez, Juanita, Berges, Alienor, Cheung, S Y Amy, Irurzun-Arana, Itziar, Goldwin, Andrew, Felicetti, Brunella, Jones, Gemma N, Lau, Alan, Frewer, Paul, Pierce, Andrew J, Clack, Glen, Stephens, Christine, Smith, Simon A, Dean, Emma, Hollingsworth, Simon J

Volltext

Defining actionable mutations for oncology therapeutic development von Carr, T. Hedley, McEwen, Robert, Dougherty, Brian, Johnson, Justin H., Dry, Jonathan R., Lai, Zhongwu, Ghazoui, Zara, Laing, Naomi M., Hodgson, Darren R., Cruzalegui, Francisco, Hollingsworth, Simon J., Barrett, J. Carl

Volltext

Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial von Lee, Jeeyun, Kim, Seung Tae, Kim, Kyung, Lee, Hyuk, Kozarewa, Iwanka, Mortimer, Peter G S, Odegaard, Justin I, Harrington, Elizabeth A, Lee, Juyoung, Lee, Taehyang, Oh, Sung Yong, Kang, Jung-Hun, Kim, Jung Hoon, Kim, Youjin, Ji, Jun Ho, Kim, Young Saing, Lee, Kyoung Eun, Kim, Jinchul, Sohn, Tae Sung, An, Ji Yeong, Choi, Min-Gew, Lee, Jun Ho, Bae, Jae Moon, Kim, Sung, Kim, Jae J, Min, Yang Won, Min, Byung-Hoon, Kim, Nayoung K D, Luke, Sally, Kim, Young Hwa, Hong, Jung Yong, Park, Se Hoon, Park, Joon Oh, Park, Young Suk, Lim, Ho Yeong, Talasaz, AmirAli, Hollingsworth, Simon J, Kim, Kyoung-Mee, Kang, Won Ki

Volltext

Biomarker‐driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum‐based chemotherapy von Park, Sehhoon, Shim, Joonho, Mortimer, Peter G. S., Smith, Simon A., Godin, Robert E., Hollingsworth, Simon J., Kim, Hee‐Jung, Jung, Hyun Ae, Sun, Jong‐Mu, Park, Woong‐Yang, Ahn, Jin Seok, Ahn, Myung‐Ju, Lee, Se‐Hoon, Park, Keunchil

Volltext

AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity von Fok, Jacqueline H. L., Ramos-Montoya, Antonio, Vazquez-Chantada, Mercedes, Wijnhoven, Paul W. G., Follia, Valeria, James, Neil, Farrington, Paul M., Karmokar, Ankur, Willis, Sophie E., Cairns, Jonathan, Nikkilä, Jenni, Beattie, David, Lamont, Gillian M., Finlay, M. Raymond V., Wilson, Joanne, Smith, Aaron, O’Connor, Lenka Oplustil, Ling, Stephanie, Fawell, Stephen E., O’Connor, Mark J., Hollingsworth, Simon J., Dean, Emma, Goldberg, Frederick W., Davies, Barry R., Cadogan, Elaine B.

Volltext

The impact of germline mutations on targeted therapy von Smith, Simon A, French, Tim, Hollingsworth, Simon J

Volltext

Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epidermal Growth Factor Receptor, in... von PAZ-ARES, Luis G, GOMEZ-ROCA, Carlos, HOLLINGSWORTH, Simon, BASELGA, José, UMANA, Pablo, MANENTI, Luigi, TABERNERO, Josep, DELORD, Jean-Pierre, CERVANTES, Andres, MARKMAN, Ben, CORRAL, Jesus, SORIA, Jean-Charles, BERGE, Yann, RODA, Desamparados, RUSSELL-YARDE, Fiona

Volltext

Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial von Kim, Seung Tae, Lee, Sujin, Park, Minhwa, Park, Se Hoon, Park, Joon Oh, Lim, Ho Yeong, Park, Young Suk, Kang, Won Ki, Gangolli, Esha A., Shin, Hyeongchan, Kim, Kyoung-Mee, Hollingsworth, Simon J., Mortimer, Peter G.S., Lee, Jeeyun

Volltext

The Challenges of Precision Oncology Drug Development and Implementation von Hollingsworth, Simon J., Biankin, Andrew V.

Volltext

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer von Tutt, Andrew N.J, Garber, Judy E, Kaufman, Bella, Viale, Giuseppe, Fumagalli, Debora, Rastogi, Priya, Gelber, Richard D, de Azambuja, Evandro, Fielding, Anitra, Balmaña, Judith, Domchek, Susan M, Gelmon, Karen A, Hollingsworth, Simon J, Korde, Larissa A, Linderholm, Barbro, Bandos, Hanna, Senkus, Elżbieta, Suga, Jennifer M, Shao, Zhimin, Pippas, Andrew W, Nowecki, Zbigniew, Huzarski, Tomasz, Ganz, Patricia A, Lucas, Peter C, Baker, Nigel, Loibl, Sibylle, McConnell, Robin, Piccart, Martine, Schmutzler, Rita, Steger, Guenther G, Costantino, Joseph P, Arahmani, Amal, Wolmark, Norman, McFadden, Eleanor, Karantza, Vassiliki, Lakhani, Sunil R, Yothers, Greg, Campbell, Christine, Geyer, Charles E

Volltext

Advanced qRT-PCR technology allows detection of the cholecystokinin 1 receptor (CCK1R) expression in human pancreas von Galindo, Jose, Jones, Neil, Powell, Garth L, Hollingsworth, Simon J, Shankley, Nigel

Volltext

Neuromedin U stimulates contraction of human long saphenous vein and gastrointestinal smooth muscle in vitro von Jones, Neil A., Morton, Magda F., Prendergast, Clodagh E., Powell, Garth L., Shankley, Nigel P., Hollingsworth, Simon J.

Volltext

VIOLETTE: A randomized phase II study to assess DNA damage response inhibitors in combination with olaparib (Ola) vs Ola monotherapy in patients (pts) with metastatic, triple-negat... von Tutt, Andrew, Stephens, Christine, Frewer, Paul, Pierce, Andrew, Rhee, Joon, So, Karen, Ottesen, Lone, Dean, Emma, Hollingsworth, Simon J.

Volltext

Ceralasertib (AZD6738), an oral ATR kinase inhibitor, in combination with carboplatin in patients with advanced solid tumors: a Phase I study von Yap, Timothy, Krebs, Matthew, Postel-Vinay, Sophie, El-Khouiery, Anthony, Soria, Jean-Charles, Lopez, Juanita, Berges, Alienor, Cheung, S. Y. Amy, Irurzan-Arana, Itziar, Goldwin, Andrew, Felicetti, Brunella, Jones, Gemma, Lau, Alan, Frewer, Paul, Pierce, Andrew, Clack, Glen, Stephens, Christine, Smith, Simon, Dean, Emma Jane, Hollingsworth, Simon J

Volltext

VIOLETTE: A randomized phase II study to assess the DNA damage response inhibitors AZD6738 or AZD1775 in combination with olaparib (Ola) versus Ola monotherapy in patients (pts) wi... von Tutt, Andrew, Stephens, Christine, Frewer, Paul, Pierce, Andrew, Rhee, Joon, Edgington, Sarah, Ottesen, Lone, Ah-See, Mei-Lin, Hollingsworth, Simon J., Dean, Emma

Volltext

Correction to: The Cancer Research UK Stratified Medicine Programme as a model for delivering personalised cancer care von Cerone, Maria Antonietta, Mills, Tara C., Sharpe, Rowena, McBride, David, MacDonald, Moira, MacMahon, Suzanne, Mugalaasi, Hood, Rehal, Pauline, Rettino, Alessandro, Roberts, Helen, Ross, Mark, White, Donald Edward, Peden, John, Rawlinson, Janette, Ho, Steffan N., Hollingsworth, Simon, Popat, Sanjay, Middleton, Gary, Johnson, Peter, Swanton, Charles

Volltext

The Cancer Research UK Stratified Medicine Programme as a model for delivering personalised cancer care von Cerone, Maria Antonietta, Mills, Tara C., Sharpe, Rowena, McBride, David, MacDonald, Moira, MacMahon, Suzanne, Mugalaasi, Hood, Rehal, Pauline, Rettino, Alessandro, Roberts, Helen, Ross, Mark, White, Donald Edward, Peden, John, Rawlinson, Janette, Ho, Steffan N., Hollingsworth, Simon, Popat, Sanjay, Middleton, Gary, Johnson, Peter, Swanton, Charles

Volltext